Singular Genomics Sys Analyst Ratings
Singular Genomics Sys Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/17/2022 | 11.94% | UBS | $10 → $4.5 | Downgrades | Buy → Neutral |
| 08/10/2022 | -25.37% | B of A Securities | → $3 | Downgrades | Buy → Underperform |
| 08/10/2022 | -12.94% | Goldman Sachs | → $3.5 | Downgrades | Buy → Neutral |
| 07/14/2022 | 24.38% | Goldman Sachs | $9.5 → $5 | Maintains | Buy |
| 05/11/2022 | 136.32% | Goldman Sachs | $11 → $9.5 | Maintains | Buy |
| 04/13/2022 | 173.63% | Goldman Sachs | $17 → $11 | Maintains | Buy |
| 01/07/2022 | 422.39% | B of A Securities | → $21 | Upgrades | Neutral → Buy |
| 06/21/2021 | 546.77% | B of A Securities | → $26 | Initiates Coverage On | → Neutral |
| 06/21/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 06/21/2021 | 646.27% | JP Morgan | → $30 | Initiates Coverage On | → Overweight |
| 06/21/2021 | 770.65% | Goldman Sachs | → $35 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/17/2022 | 11.94% | 瑞银（UBS） | 10 美元 → 4.5 美元 | 降级 | 买入 → 中性 |
| 08/10/2022 | -25.37% | B of A 类证券 | → 3 美元 | 降级 | 买入 → 表现不佳 |
| 08/10/2022 | -12.94% | 高盛 | → 3.5 美元 | 降级 | 买入 → 中性 |
| 07/14/2022 | 24.38% | 高盛 | 9.5 美元 → 5 美元 | 维护 | 买 |
| 05/11/2022 | 136.32% | 高盛 | 11 美元 → 9.5 美元 | 维护 | 买 |
| 2022 年 4 月 13 日 | 173.63% | 高盛 | 17 美元 → 11 美元 | 维护 | 买 |
| 2022 年 7 月 1 日 | 422.39% | B of A 类证券 | → 21 美元 | 升级 | 中性 → 买入 |
| 06/21/2021 | 546.77% | B of A 类证券 | → 26 美元 | 启动覆盖范围开启 | → 中立 |
| 06/21/2021 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
| 06/21/2021 | 646.27% | 摩根大通 | → 30 美元 | 启动覆盖范围开启 | → 超重 |
| 06/21/2021 | 770.65% | 高盛 | → 35 美元 | 启动覆盖范围开启 | → 购买 |
Singular Genomics Sys Questions & Answers
奇异基因组学系统问题与解答
The latest price target for Singular Genomics Sys (NASDAQ: OMIC) was reported by UBS on August 17, 2022. The analyst firm set a price target for $4.50 expecting OMIC to rise to within 12 months (a possible 11.94% upside). 7 analyst firms have reported ratings in the last year.
瑞银于2022年8月17日公布了奇异基因组系统（纳斯达克股票代码：OMIC）的最新目标股价。该分析公司将目标股价定为4.50美元，预计OMIC将在12个月内升至12个月内（可能上涨11.94％）。去年有7家分析公司公布了评级。
The latest analyst rating for Singular Genomics Sys (NASDAQ: OMIC) was provided by UBS, and Singular Genomics Sys downgraded their neutral rating.
瑞银提供了Singular Genomics Sys（纳斯达克股票代码：OMIC）的最新分析师评级，奇异基因组系统下调了中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Singular Genomics Sys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Singular Genomics Sys was filed on August 17, 2022 so you should expect the next rating to be made available sometime around August 17, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Singular Genomics Sys的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Singular Genomics Sys的最新评级是在2022年8月17日发布的，因此您应该预计下一个评级将在2023年8月17日左右公布。
While ratings are subjective and will change, the latest Singular Genomics Sys (OMIC) rating was a downgraded with a price target of $10.00 to $4.50. The current price Singular Genomics Sys (OMIC) is trading at is $4.02, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的奇异基因组学系统（OMIC）评级已下调，目标股价为10.00美元至4.50美元。Singular Genomics Sys（OMIC）目前的交易价格为4.02美元，超出了分析师的预期区间。